Blend outlines path to 10%-15% incremental top line growth in 2027 as Autopilot moves to paid tiers in late June

Profound outlines ~$25M 2026 revenue, anticipates FDA clearance for Siemens Free integration by year-end

2026/05/08

Allient outlines $12M-$15M FY2026 CapEx while aiming to complete Dothan transition by end of Q3

2026/05/08

Phibro outlines FY2026 net sales of $1.46B-$1.5B as adjusted EBITDA guidance moves to $247M-$255M

2026/05/08

Arrowhead anticipates SHASTA-3/4 topline in Q3 while planning an SHTG sNDA before end of 2026

2026/05/08